Price Alert

Liquidia Corporation (LQDA)

NASDAQ: LQDA · Real-Time Price · USD

26.27

0.18 (0.69%)

At close: Aug 15, 2025, 1:13 PM

0.69% (1D)

Bid	26.26
Market Cap	2.26B
Revenue (ttm)	14.14M
Net Income (ttm)	-127.83M
EPS (ttm)	-1.82
PE Ratio (ttm)	-14.43
Forward PE	-157.04
Analyst	Buy

Ask	26.28
Volume	1,390,258
Avg. Volume (20D)	2,799,741
Open	26.53
Previous Close	26.09
Day's Range	25.75 - 26.53
52-Week Range	8.26 - 26.65
Beta	0.15

About LQDA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LQDA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LQDA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Liquidia has released their quartely earnings on Aug 12, 2025:

Revenue of $8.84M exceeds estimates by $4.92M, with 141.51% YoY growth.

EPS of -0.49 misses estimates by -0.08, with -32.43% YoY decline.

Next Earnings Release

Liquidia Corporation is scheduled to release its earnings on Nov 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

+13.68%

Liquidia shares are trading higher. The company re... Unlock content with Pro Subscription

2 months ago

-16.87%

Liquidia shares are trading lower in reaction to Insmed after its drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.

News

2 days ago · benzinga.com

Liquidia Analysts Raise Their Forecasts Following Q2 Results

Liquidia Corporation LQDA reported a loss for the second quarter on Tuesday.

3 days ago · zacks.com

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates

Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.37 per share a year ago.

3 days ago · benzinga.com

Why Is Liquidia Stock Trading Higher On Tuesday?

Liquidia Corporation LQDA reported on Tuesday a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents.

2 days ago · seekingalpha.com

Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript

1 month ago · seekingalpha.com

What Next For Liquidia After Launch?

Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several billion dollars. Market sentiment remains skeptical, pricing in limited Yutre...

2 months ago · https://thefly.com

Liquidia price target lowered by $2 at BofA, here's why

Liquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun

2 months ago · benzinga.com

These Analysts Boost Their Forecasts On Liquidia

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hyperten...